At Daiichi Sankyo UK, we are committed to maintaining the highest standards of integrity, transparency, and accountability in all our external engagements. We believe that openness is fundamental to building trust and fostering meaningful, responsible relationships across the healthcare ecosystem.
In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, we publicly disclose Transfers of Value made to relevant stakeholders. These disclosures provide a clear and accessible view of the nature and scope of our interactions and are published annually, covering the previous three years.
Our collaborations with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) play a vital role in advancing medical innovation, improving clinical practice, and ultimately enhancing patient outcomes.
To ensure transparency, we disclose all reportable Transfers of Value associated with these engagements in line with our commitment to openness and accountability.
Disclosure of Transfer of Value for Healthcare Professionals and Healthcare Organisations can be found here
At Daiichi Sankyo UK, our commitment to “Passion for Innovation. Compassion for Patients” extends beyond medicines. Patient centricity is embedded in everything we do. By understanding the needs of patients and caregivers, we work to support better outcomes and enrich quality of life.
We engage with Patient Organisations, Patients, Members of the Public, and Journalists as part of our broader commitment to advancing healthcare and supporting the communities we serve.
Disclosure data is grouped and available by year via the links below:
UK/DSC/06/26/0014 - June 2026
